packageLuseogliflozin

luseogliflozin

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Luseogliflozin is an SGLT2 inhibitor studied for the treatment of type 2 diabetes. It is not authorised in the European Union and remains investigational.

Summary written by glm-5.3-flash from Wikidata Q27275212 and the WHO ATC classification; not checked by a person.

name:luseogliflozin
ATC codes:A10BK07
DrugBank:DB12214
PubChem CID:11988953
ChEBI:134725
Wikidata:Q27275212
formula:C23H30O6S
molar mass:434.547 g/mol (PubChem CID 11988953)
logP:2.9 (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown